Autres langues Grace Therapeutics, Inc.

Actions

GRCE

US00439U1043

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
2,120 ^USD	-1,85%		+0,47%	-38,73%

24/08	Grace Therapeutics dépose une demande de revente portant sur un maximum de 4,8 millions d'actions	MT
13/08	Grace Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI

Autres langues

03/09	Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
24/08	Grace Therapeutics Files for Resale of Up to 4.8 Million Shares
13/08	Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026
13/08	Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
13/08	Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026
06/08	Grace Therapeutics, Inc. announced that it has received $9.999998 million in funding
05/08	Grace Therapeutics Announces $10 Million Private Placement
04/08	Grace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding
28/07	Grace Therapeutics Receives Type a Meeting Minutes from FDA and Provides Update on GTx-104 Clinical-Stage Injectable Formulation
28/07	Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
29/06	Grace Therapeutics, Inc.(NasdaqCM:GRCE) added to Russell Microcap Value Benchmark Index
29/06	Grace Therapeutics, Inc.(NasdaqCM:GRCE) added to Russell 3000E Index
29/06	Grace Therapeutics, Inc.(NasdaqCM:GRCE) added to Russell Microcap Index
29/06	Grace Therapeutics, Inc.(NasdaqCM:GRCE) added to Russell 3000E Value Benchmark
18/06	Grace Therapeutics Provides Update On GTx-104 NDA Resubmission And Reports Phase 3 STRIVE-ON Safety Trial Data
18/06	Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
18/06	Grace: Fiscal Q4 Earnings Snapshot
18/06	Grace Therapeutics, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026
18/06	Grace Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
27/04	Grace Therapeutics : Overview
23/04	Grace Therapeutics Shares Fall After FDA Flags Issues in Aneurysm Treatment Application
23/04	FDA declines Grace's stroke drug over manufacturing and packaging issues, shares slump
23/04	Grace Therapeutics Gets FDA Complete Response Letter for GTx-104
23/04	Grace Therapeutics says FDA issued Complete Response Letter for GTx-104 NDA
23/04	US FDA declines to approve Grace Therapeutics' drug for a type of stroke